{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-014236","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.132389+00:00","generated_at":"2026-06-04T03:25:09.412671+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocugen provides FY2023 update: FDA alignment for OCU400 Phase 3, RMAT designation, cash $39.5M, restatement planned","bullets":["FDA alignment for broad retinitis pigmentosa indication in Phase 3 trial of OCU400; RMAT designation granted.","Completed cohort 1 dosing for OCU410 (GA) and OCU410ST (Stargardt) in Phase 1/2 trials.","Cash, cash equivalents, and investments $39.5M as of Dec 31, 2023, vs. $90.9M a year earlier; runway into Q4 2024.","Intends to restate FY2022 and first three quarters of 2023 financials due to non-cash accounting error; no cash impact.","OCU500 mucosal vaccine selected for NIAID Project NextGen; clinical trials expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-014236","json":"https://secwatch.observer/filing/0001628280-24-014236.json","markdown":"https://secwatch.observer/filing/0001628280-24-014236.md","text":"https://secwatch.observer/filing/0001628280-24-014236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/ocgn-20240402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:25:09.412671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb2a36ec90f65fb5073c5f680ff1a87a54a3bcb3","claim":"Ocugen, Inc. reported financial results for the fourth quarter and the fiscal year ended December 31, 2023.","evidence_excerpt":"On April 2, 2024, Ocugen, Inc. (the \"Company\") issued a press release announcing certain financial data for the fourth quarter and the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}